Search PubMed⌕ Search

Biomedical subjects

M Wysocki

Publications and source records attributed to M Wysocki.

188 records · Page 11Linked to original sources
PubMedDate not supplied

Systemic and renal hemodynamic effects of single oral doses of felodipine in patients with refractory hypertension receiving chronic therapy with beta-blockers and diuretics.

In 12 patients with primary hypertension (World Health Organization stage 2) inadequately controlled by chronic standard triple therapy, hydralazine was replaced by felodipine, a new vasodilating dihydropyridine derivative, and the acute effects of the drug on central and renal hemodynamics were monitored. Following baseline measurements, an oral solution of felodipine (0.075-0.1 mg/kg) was given. Fifteen minutes after intake of felodipine, a significant hypotensive response was observed, and the maximal response (23% reduction of mean arterial pressure) occurred after 30 min. There was a linear relationship between the changes in mean arterial pressure and log plasma concentration of felodipine. Cardiac output (dye dilution) increased during maximal blood pressure reduction, from 5.3 +/- 1.0 to 6.6 +/- 2.4 L/min (p less than 0.01), partly because of increased heart rate from 57 +/- 4 to 65 +/- 9.1 beats/min (p less than 0.01) and partly because of increased stroke volume from 93 +/- 14 to 104 +/- 33 ml (p less than 0.05). Renal plasma flow (para-aminohippuric acid clearance) increased significantly (p less than 0.05) from 343 +/- 138 to 391 +/- 154 ml/min, while glomerular filtration rate ([51Cr]EDTA clearance) did not change. Arteriovenous noradrenaline difference increased 36% during felodipine therapy, when corrected for blood flow increase. We conclude that felodipine is a calcium inhibitor with potent vasodilating properties.

Administration, Oral↗
PubMedDate not supplied

Effect of novel platinum complexes on survival rate of B16 and Cl S91 melanoma cells and oxidation stress in vitro.

BACKGROUND: The aim of study was the assessment of two novel platinum complexes and their cytotoxic effect on murine melanoma cells. The evaluation of possible oxidation stress in neoplastic cells coexistent with the effect of these cytostatic agents. MATERIAL AND METHODS: Two lines of murine metastatic melanomas: B16 and Cl S91 were selected for the experiments. Two platinum compounds were tested: cis-dichloro(dimethylsulphoxide)(1-beta-D-ribofuranosyl-1,2,4-triazol-3-carboxyamide)platinum (II) called Pt-complex 1 and chloro(dimethylsulphoxide)(1-beta-D-ribofuranosyl-1,2,4-triazol-3-carboxyamide)platinum (II) called Pt-complex 2. Melanoma cells were incubated for 24 hours with the platinum complexes mentioned above and culture medium at the concentration of 0.01, 0.05 and 0.5 mg/ml. Survival rate of melanoma cells, superoxide dismutase (SOD) activity, the concentration of thiobarbituric acid reactive substances (TBARS) and the content of conjugated dienes were estimated. RESULTS: A number of statistically significant relationships between analysed parameters were observed. Negative correlation ratios were found between increasing levels of analysed platinum complexes and the survival rate of the cells of both melanoma lines as well as between the survival rate of Cl S91 melanoma cells and the level of lipid peroxidation products and SOD activity. On the other hand, there was a positive correlation between increasing platinum complexes and the level of lipid peroxidation products as well as between the survival rate of B16 melanoma cells and SOD activity and the content of CD. CONCLUSIONS: Oxygen free radicals may play an important role in the development of melanoma and cytostatic agents disturb the balance between generation and removal of reactive oxygen forms in melanoma cells.

Animals↗
PubMedDate not supplied

[Treatment regimen for children and adolescents with Hodgkin's disease designed to decrease late complications of radiotherapy].

Between 1997 to 1999 in 9 centres of the Polish Paediatlic Leukemia/Lymphoma Study Group, 167 children and adolescents (aged 2-19 years) with stage 1 to IV Hodgkin's disease (HD) were treated according to a regimen with a limited use of radiotherapy (RT). All patients received B-DOPA and MVPP chemotherapy. The number of cycles of chemotherapy was adjusted in respective risk groups. In 13 children with stage IA and IIA disease with favourable prognostic factors chemotherapy alone was used. In other patients the dose of RT applied to lymphatic regions was 15-46,4 Gy. In case of a small tumour at presentation and good response to initial chemotherapy the RT dose was 15-16 Gy. In other cases doses of 25-30 Gy were planned. The use of higher doses, particularly exceeding 35 Gy, in eleven patients, was not justified. Among all the 167 patients, three oftliem (1.2%) with advanced disease (Stage III-1V) did not achieve first remission. The 4-year overall survival (OS), relapse free survival (RFS) and event free survival (EPS) were 99%. 93% and 90%, respectively. Relapses occurred in 8 children (first remission lasted for 4-29 (median = 9 months). All 13 children in whom chemotherapy alone was used remain in first remission. In the group of children who received RT in the dose of 15-16 Gy relapse occurred in one child. Our preliminary analysis indicates that limited use of RT in selected cases of HD in children and adolescents did not show worse results of treatment. However, the assessment of possible influence of this regimen on the decreased rate of late complications requires longer follow-up.

Adolescent↗